Bristol Myers Squibb (NYSE:BMY) Trading Down 1.9% – Here’s Why

Shares of Bristol Myers Squibb Company (NYSE:BMY) dropped 1.9% during mid-day trading on Tuesday . The company traded as low as $53.88 and last traded at $54.2030. Approximately 15,343,178 shares changed hands during trading, an increase of 17% from the average daily volume of 13,144,328 shares. The stock had previously closed at $55.26.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY signed a collaboration with Microsoft to use its AI-enabled radiology platform to speed early detection of lung cancer — a strategic move that could strengthen diagnostics, clinical trial readouts and long-term oncology positioning. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: Scotiabank highlighted BMY as an appealing 2026 investment and raised its price target (reported lift to $60 from $53), which could support investor sentiment if other analysts follow. Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026
• Positive Sentiment: BMS extended a deal with Syngene, keeping manufacturing and R&D continuity intact — a modest operational positive for supply chain stability. BMS extends deal with Syngene
• Neutral Sentiment: A Zacks comparison piece contrasts BMY with GSK on portfolio and prospects; useful for longer-term allocation decisions but not an immediate catalyst. BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
• Neutral Sentiment: Coverage in ETF/blue‑chip lists and investor videos (dividend ETF roundups, “top blue‑chip” buys) reinforces BMY’s image as a reliable large-cap dividend/defensive healthcare name but is more background than a fresh catalyst. 3 Dividend Income ETFs That Offer High Yields And Growth 2 Top Blue-Chip Stocks to Buy and Hold in 2026
• Neutral Sentiment: Mentions in broader investor roundups (e.g., MarketBeat on Buffett-related names) keep BMY in view for income/ value investors but don’t constitute direct drivers. 2 Buffett Stocks to Load Up On—And 1 to Ditch (BMY)

Wall Street Analyst Weigh In

BMY has been the subject of several recent research reports. Scotiabank reissued a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Citigroup reaffirmed a “neutral” rating and set a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 7th. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $46.00 to $65.00 in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company lifted their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.86.

Bristol Myers Squibb Trading Down 1.9%

The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The company has a market cap of $110.34 billion, a P/E ratio of 18.31 and a beta of 0.29. The firm’s 50 day moving average is $52.07 and its two-hundred day moving average is $48.19.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 85.14%.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth about $1,554,154,000. Charles Schwab Investment Management Inc. boosted its stake in Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after purchasing an additional 9,171,098 shares during the period. Man Group plc boosted its holdings in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the period. Finally, Franklin Resources Inc. raised its stake in Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after buying an additional 4,961,869 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.